UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000029294 |
|---|---|
| Receipt number | R000033491 |
| Scientific Title | Fulvestrant with additional palbociclib in advanced or metastatic HR-positive HER2-negative breast cancer after progression to fulvestrant monotherapy. -FUTURE trial a multicenter study- |
| Date of disclosure of the study information | 2017/12/01 |
| Last modified on | 2023/10/02 12:07:39 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2017/09/26 17:36:00 | ||
| 2 | Update | 2018/01/30 18:43:57 | Recruitment status |
|
| 3 | Update | 2018/03/28 10:25:14 | Public title Public title |
|
| 4 | Update | 2018/08/23 17:48:26 | Public title |
|
| 5 | Update | 2018/08/24 10:11:02 | UMIN ID1 |
|
| 6 | Update | 2018/09/28 12:00:44 | Date of protocol fixation |
|
| 7 | Update | 2019/09/05 16:36:45 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Address Last name of contact person Last name of contact person Zip code Address Address Organization Organization Address Address Tel |
|
| 8 | Update | 2019/09/05 16:40:17 | Date of IRB Last follow-up date |
|
| 9 | Update | 2021/07/15 13:59:02 | Last name of contact person Last name of contact person Division name Name of person sending information Name of person sending information Division name |
|
| 10 | Update | 2021/07/15 15:39:48 | Homepage URL |
|
| 11 | Update | 2023/04/03 10:13:57 | Recruitment status Last follow-up date |
|
| 12 | Update | 2023/10/02 12:07:39 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Organization Organization Division name Division name Zip code Address Address |
